Bausch + Lomb (BLCO.TO) fell 10% in U.S. pre-market trading on Wednesday after reporting a swing to a first-quarter adjusted loss.
The adjusted loss was US$54 million, or US$0.07 per share, compared with adjusted net income of US$24 million, or $0.07 per share, for the prior year period. The result missed a consensus analyst estimate of US$0.02 per share, according to Capital IQ. The profit figures exclude most one-time items, including the acquisition of Whitecap Biosciences and the voluntary recall of certain enVista products
Revenue increased 3% to US$1.137 billion.
Bausch + Lomb updated its 2025 outlook to account for the estimated impact of the enVista intraocular lens recall and foreign exchange. The company now expects revenue of US$5 billion to US$5.1 billion, up from February's forecast of US$4.95 billion to US$5.05 billion. It also expects a full-year one-time impact of US$55 million for the enVista recall on revenue.
The company's shares were last seen down US$1.43 to US$12.29 in New York trading.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.